ProteinQure Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 32

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Latest Deal Amount
  • $104K

  • Investors
  • 30

ProteinQure General Information

Description

Operator of a biotech company intended to focus on the design of novel exotic peptides with broad therapeutic applications. The company specializes in leveraging quantum computing, molecular simulations, and reinforcement learning to facilitate novel therapeutics engineering, enabling researchers and drug developers to engineer and design protein structures with efficiency.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 108 College Street
  • Suite 580
  • Toronto, Ontario M5G 0C6
  • Canada
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Biotechnology
Corporate Office
  • 108 College Street
  • Suite 580
  • Toronto, Ontario M5G 0C6
  • Canada

ProteinQure Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ProteinQure Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
15. Accelerator/Incubator 01-Jan-2025 $104K Completed Clinical Trials - Phase 1
14. Later Stage VC (Series A) 25-Sep-2024 Completed Clinical Trials - Phase 1
13. Later Stage VC 01-Jan-2024 Completed Clinical Trials - Phase 1
12. Secondary Transaction - Private 24-Jan-2022 Completed Clinical Trials - Phase 1
11. Accelerator/Incubator 14-Oct-2020 Completed Clinical Trials - Phase 1
10. Accelerator/Incubator 09-Oct-2020 Completed Clinical Trials - Phase 1
9. Accelerator/Incubator Completed Clinical Trials - Phase 1
8. Seed Round 29-Jul-2019 Completed Clinical Trials - Phase 1
7. Accelerator/Incubator 12-Sep-2018 $602K Completed Clinical Trials - Phase 1
6. Seed Round 01-Jul-2018 $472K $602K Completed Clinical Trials - Phase 1
To view ProteinQure’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

ProteinQure Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotech company intended to focus on the design of novel exotic peptides with broad therapeutic applicatio
Drug Discovery
Toronto, Canada
32 As of 2026

Boston, MA
 

Toronto, Canada
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ProteinQure Competitors (63)

One of ProteinQure’s 63 competitors is Manifold Bio, a Venture Capital-Backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Manifold Bio Venture Capital-Backed Boston, MA
Deep Genomics Venture Capital-Backed Toronto, Canada
LabGenius Therapeutics Venture Capital-Backed London, United Kingdom
Terray Therapeutics Venture Capital-Backed Monrovia, CA
Protai Bio Venture Capital-Backed Ramat Gan, Israel
You’re viewing 5 of 63 competitors. Get the full list »

ProteinQure Patents

ProteinQure Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260183411-A1 Targeting sortilin Pending 10-May-2024
WO-2025235912-A2 Targeting sortilin Pending 10-May-2024
WO-2025235912-A3 Targeting sortilin Pending 10-May-2024
WO-2025222300-A1 Atrial natriuretic peptide constructs for targeted payload delivery to npr-c expressing cells Pending 24-Apr-2024
AU-2023389980-A1 Targeting sortilin Pending 06-Dec-2022 A61K47/645
To view ProteinQure’s complete patent history, request access »

ProteinQure Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ProteinQure Investors (30)

Investor Name Investor Type Holding Investor Since Participating Rounds
Federal Economic Development Agency for Southern Ontario Government Minority
Ontario Genomics Accelerator/Incubator Minority
Canadian Medical Isotope Ecosystem Venture Capital Minority
Esalen Ventures Venture Capital Minority
Kensington Capital Partners PE/Buyout Minority
You’re viewing 5 of 30 investors. Get the full list »

ProteinQure FAQs

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process